Literature DB >> 20524575

Single-stage canal wall-down tympanoplasty: long-term results and prognostic factors.

Luca Oscar Redaelli de Zinis1, Daniela Tonni, Maria Grazia Barezzani.   

Abstract

OBJECTIVES: We sought to identify factors associated with anatomic and functional results of canal wall-down tympanoplasty.
METHODS: One hundred eighty-nine primary or relapsing cholesteatomas were consecutively operated on by a single surgeon. Cholesteatoma recurrence rates were evaluated. Predictive values of the patient, disease, and surgical characteristics on cholesteatoma recurrence were estimated. The effect of these variables on keratin pearl development, recurrent otorrhea or granulation tissue formation, and hearing function was tested.
RESULTS: The mean follow-up was 8 years (range, 4 to 15 years). The cholesteatoma relapse rate (+/- SE) estimated by the Kaplan-Meier method was 2.1% +/-1.1%. No variables were associated with relapsing disease. The log-rank test showed a significantly higher probability of keratin pearls in male patients (16.7% versus 2.1%; p = 0.001), young patients (less than 16 years; 51.4% versus 6.2%; p = 0.0001), patients with unencapsulated cholesteatomas (19.5% versus 5.3%; p = 0.06), patients with petrous or accessory cellularity invasion (17.9% versus 7.1%; p = 0.02), and patients with overlay myringoplasty (25% versus 7.9%; p = 0.03). Recurrent otorrhea and granulation tissue were associated with homograft temporalis fascia myringoplasty (14.3% versus 3.8%; p = 0.04). The overall postoperative air-bone gap was within 20 dB in 30.7%; it was within 20 dB in 43.9% (47/107) for intact or reconstructed ossicular chains and in 13.4% (11/82) for nonreconstructed, eroded ossicular chains (p = 0.0001). The air-bone gap was within 20 dB in 42.6% (46/108) when the mucosa of the tympanic cavity was normal and in 14.8% (12/81) when there was granulation tissue within the tympanic cavity (p = 0.0001).
CONCLUSIONS: Single-stage canal wall-down tympanoplasty is an appropriate treatment for acquired tympanomastoid cholesteatoma.

Entities:  

Mesh:

Year:  2010        PMID: 20524575     DOI: 10.1177/000348941011900506

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  7 in total

Review 1.  First report of otitis externa caused by Schizophyllum commune and review of the literature.

Authors:  Tadeja Matos; Rok Tomazin; Saba Battelino
Journal:  Wien Klin Wochenschr       Date:  2016-01-22       Impact factor: 1.704

2.  Five-year postoperative outcomes of modified staged canal wall up tympanoplasty for primary acquired cholesteatoma.

Authors:  Masahiro Komori; Naoaki Yanagihara; Jun Hyodo; Ryosei Minoda; Yasuyuki Hinohira
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-11       Impact factor: 2.503

3.  Trans-canal endoscopic ear surgery and canal wall-up tympano-mastoidectomy for pediatric middle ear cholesteatoma.

Authors:  Eran Glikson; Gilad Feinmesser; Doron Sagiv; Michael Wolf; Lela Migirov; Yisgav Shapira
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-08-03       Impact factor: 2.503

4.  Outcomes of Using Otoendoscopy During Surgery for Cholesteatoma.

Authors:  Alaa Eldin M Elfeky; Alaa O Khazbzk; Wail F Nasr; Tarek A Emara; Mohamed W Elanwar; Hazem S Amer; Yasser A Fouad
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-02-06

5.  Vascular Strip Cholesteatoma-A Case Report.

Authors:  Ajay M Bhandarkar; Samarth Goyal; Manna Valiathan; Kailesh Pujary
Journal:  Iran J Otorhinolaryngol       Date:  2019-09

6.  Trends and Healthcare Use Following Different Cholesteatoma Surgery Types in a National Cohort, 2003-2019.

Authors:  Zhen Jason Qian; Emma D Tran; Jennifer C Alyono; Alan G Cheng; Iram N Ahmad; Kay W Chang
Journal:  Otol Neurotol       Date:  2021-10-01       Impact factor: 2.619

Review 7.  Results of endoscopic middle ear surgery for cholesteatoma treatment: a systematic review.

Authors:  L Presutti; F M Gioacchini; M Alicandri-Ciufelli; D Villari; D Marchioni
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-06       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.